M. Kovatcheva

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition

N. Socci, S. Singer, G. Schwartz, 2015, Oncotarget.

Persister cancer cells are characterized by H4K20me3 heterochromatin that defines a low inflammatory profile

Laia Richart, Jordi Capellades, Valentina Ramponi, 2024, bioRxiv.

Vitamin B12 is a limiting factor for induced cellular plasticity and tissue repair

Adrià Caballé, Dafni Chondronasiou, F. Pietrocola, 2023, Nature Metabolism.

Higher circulating Vitamin B12 is associated with lower levels of inflammatory markers in individuals at high cardiovascular risk and in naturally aged mice.

R. Lamuela-Raventós, M. Fitó, R. Casas, 2023, Journal of the science of food and agriculture.

Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

E. Caron, Adrià Caballé, M. Serrano, 2022, Cancer discovery.

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

W. Tap, A. Koff, L. Davis, 2018, Cancer cell.

ATRX is a regulator of therapy induced senescence in human cells

Heather Geiger, N. Robine, S. Singer, 2017, Nature Communications.

Senescence as a therapeutic target

M. Serrano, J. Lopez-Dominguez, Máté Maus, 2022, Cellular Senescence in Disease.

Release of mitochondrial dsRNA into the cytosol is a key driver of the inflammatory phenotype of senescent cells

Camille Stephan-Otto Attolini, E. Gavathiotis, Mate Maus, 2024, Nature communications.

Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

L. Qin, C. Antonescu, K. Manova-Todorova, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.

W. Tap, A. Koff, Marta Kovatcheva, 2017, Molecular & cellular oncology.